title: Effects of arotinolol on serum lipid and apolipoprotein levels in patients with mild essential hypertension.
abstract: Nineteen patients with mild essential hypertension received 20 mg of arotinolol daily for 12 weeks. The patients' systolic and diastolic blood pressures and pulse rate decreased significantly after arotinolol. The ratio of apolipoprotein B to apolipoprotein A-I decreased significantly after treatment. No significant changes were observed in serum and lipoprotein lipid levels, apolipoprotein levels, or in the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol. The results indicate that arotinolol is an effective antihypertensive agent with favorable effect on apolipoproteins.
authors: Department of Internal Medicine, Fukuoka University Hospital, Japan.
authors: J
authors: J
authors: Sasaki
authors: K
authors: K
authors: Handa
authors: K
authors: K
authors: Arakawa
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D001053:Apolipoproteins; D008055:Lipids; D008075:Lipoproteins, HDL; D011412:Propanolamines; D014280:Triglycerides; C024523:arotinolol; D002784:Cholesterol